- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07832370
A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)
Phase 1/2 Open-Label Trial With Extended Follow-Up to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of ALN-6457 in Participants With Symptomatic Prion Disease
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD).
In PrD, the prion protein folds into an abnormal shape. These abnormal proteins build up in the brain and cause damage to brain cells, leading to problems with thinking, memory, and movement.
ALN-6457 is designed to reduce the amount of prion protein made in the brain. ALN-6457 works by targeting the genetic "instructions" that cells use to produce this protein, with the goal of slowing or stopping disease progression.
This study is looking at:
- What side effects ALN-6457 might cause
- How well ALN-6457 works
- What is the best dose of ALN-6457 for treating prion disease
- How much ALN-6457 is in the blood and Cerebrospinal Fluid (CSF, fluid that surrounds the brain and spinal cord) at different times
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-Mail: clinicaltrials@regeneron.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
-
Participant must meet all of the criteria under either:
- sporadic CJD as described in the protocol or
- genetic PrD, as described in the protocol
-
Has a Body Mass Index (BMI) <35 kg/m2 (inclusive) at the screening visit
-
Able to understand and complete trial-related questionnaires at screening
Key Exclusion Criteria:
- Clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease (excluding prion disease) that, as assessed by the investigator, may confound the results of the trial or pose an additional risk to the participant during trial participation
- Medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) procedure or CSF circulation, as described in the protocol
- Any contraindications to undergo a brain Magnetic Resonance Imaging (MRI)
- An established allergy or intolerance to local anesthetics
- Current history of bleeding diatheses that would increase risk of bleeding upon LP
- Any malignancy that is progressing or requires active treatment, as described in the protocol
- Attempted suicide, suicidal ideation with a plan that required hospital admission and/or change in level of care within 12 months prior to screening
NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Dosissteigerung
|
Administered per the protocol
Andere Namen:
|
|
Experimental: Cohort Expansion
|
Administered per the protocol
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Zeitfenster: Through Week 156
|
Through Week 156
|
|
Severity of TEAEs
Zeitfenster: Through Week 156
|
Through Week 156
|
|
Percentage change in concentration of Neurofilament Light chain (NfL) in plasma from baseline
Zeitfenster: Through Week 130
|
Through Week 130
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Concentration of Prion Protein (PrP) in CSF
Zeitfenster: Through Week 130
|
Through Week 130
|
|
Change from baseline in concentration of PrP in CSF
Zeitfenster: Through Week 130
|
Through Week 130
|
|
Concentration of ALN-6457 and its major metabolites in plasma
Zeitfenster: Through Week 130
|
Through Week 130
|
|
Concentration of ALN-6457 and its major metabolites in CSF
Zeitfenster: Through Week 130
|
Through Week 130
|
|
Overall survival rate
Zeitfenster: At Week 52
|
At Week 52
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Clinical Trial Management, Regeneron Pharmaceuticals
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Störung der Proteinfehlfaltung
- Neurodegenerative Erkrankung
- Demenz
- Erkrankung des zentralen Nervensystems
- Infektionen des zentralen Nervensystems
- PrD
- Symptomatic Prion Disease
- Sporadic Prion Disease
- Genetic Prion Disease
- Inherited Prion Disease
- Familial Prion Disease
- Gerstmann-Straussler-Scheinker syndrome (GSS)
- Fatal familial insomnia (FFI)
- Rapidly-Progressive Dementia
- Creutzfeldt-Jakob Disease (CJD)
- Fatal Familial Insomnia
- Prion-Associated Disorder
- Prion-Induced Disorder
- Neurological Decline
- Transmissible Spongiform Encephalopathy
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Gehirns
- Erkrankungen des Nervensystems
- Psychische Störungen
- Genetische Krankheiten, angeboren
- Stoffwechselerkrankungen
- Infektionen
- Neurokognitive Störungen
- Schlaf-Wach-Störungen
- Heredodegenerative Erkrankungen, Nervensystem
- Schlafstörungen, intrinsisch
- Dyssomnien
- Schlafeinleitungs- und -erhaltungsstörungen
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Ernährungs- und Stoffwechselerkrankungen
- Demenz
- Neurodegenerative Krankheiten
- Erkrankungen des zentralen Nervensystems
- Proteostase-Mängel
- Creutzfeldt-Jakob-Syndrom
- Infektionen des zentralen Nervensystems
- Schlaflosigkeit, tödliche familiäre
- Prionenkrankheiten
- Gerstmann-Straussler-Scheinker-Krankheit
Andere Studien-ID-Nummern
- ALN-6457-PD-25129
- 2026-526727-21-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-Sharing-Zeitrahmen
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-Sharing-Zugriffskriterien
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .